Clinical trials: Sitagliptin, completed
Type 2 Diabetes Mellitus
MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes Mellitus
This Phase III clinical trial will examine the efficacy, safety, and tolerability of the addition of MK-0431/ONO-5435 to Japanese patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on diet/exercise…
- Trial name
- NCT00854035
- Testing
- MK-0431/ONO-5435
- Where
- 7 sites in Japan
- Volunteers
- 266 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receving treatment with metformin and pioglitazone and…
- Trial name
- NCT01106690
- Testing
- Canagliflozin, Sitagliptin, Metformin
- Where
- 83 sites in United States, Canada and 9 more
- Volunteers
- 344 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07417631
- Testing
- Dulaglutide, Sitagliptin
- Where
- United States
- Volunteers
- 300,000 people
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus Type 2
Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data
Rationale: In order to compare the real-world use of commonly prescribed second-line oral diabetes therapies, real-world data comparing patients receiving treatment with dapagliflozin vs sitagliptin are needed, and limited…
- Trial name
- NCT03078049
- Where
- United States
- Volunteers
- 11,971 people
- Sponsor
- AstraZeneca
Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.
- Trial name
- GRADE (NCT01794143)
- Testing
- Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide)
- Where
- 36 sites in United States
- Volunteers
- 7,850 people
- Sponsor
- GRADE Study Group
Diabetes Mellitus, Type 2
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from…
- Trial name
- NCT00734474
- Testing
- LY2189265, Sitagliptin, Metformin
- Where
- 99 sites in United States, Canada and 11 more
- Volunteers
- 1,202 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type II
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086515
- Testing
- Sitagliptin (MK0431), Metformin, Pioglitazone
- Volunteers
- 701 people
- Sponsor
- Merck Sharp & Dohme LLC
Type2 Diabetes
Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes
Glucagon-like peptide-1(GLP-1) is secreted during a meal and increases glucose induced insulin secretion. The enzyme dipeptidyl peptidase 4(DPP-4) cleaves intact GLP-1 within minutes and DPP-4 inhibitors are therefore used for…
- Trial name
- NEPT2D (NCT03893526)
- Testing
- Entresto, Sitagliptin, Valsartan
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- University of Copenhagen
Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent
A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)
A study to see if better control of type 2 diabetes can occur in patients taking a stable dose of metformin when they are also provided either sitagliptin or glimepiride.
- Trial name
- NCT00701090
- Testing
- sitagliptin, Comparator: glimepiride, open-label metformin
- Volunteers
- 1,035 people
- Sponsor
- Merck Sharp & Dohme LLC
Type2 Diabetes, Myocardial Infarction
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events
The purpose of this study is to compare the risk of cardiovascular events associated with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in comparison with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors among…
- Conditions
- Type2 Diabetes, Myocardial Infarction, Ischemic Stroke, Cardiovascular Death
- Trial name
- NCT03939624
- Testing
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors, Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Where
- Canada
- Volunteers
- 419,734 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)
The purpose of this study is to evaluate the efficacy and safety of sitagliptin and MK0431A in comparison to a commonly used medication in patients with type 2 diabetes.
- Trial name
- NCT00541450
- Testing
- Comparator: sitagliptin phosphate (sitagliptin), sitagliptin phosphate (+) metformin hydrochloride, Comparator: pioglitazone
- Volunteers
- 492 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Treatment of Diabetes After Gastric Bypass With Sitagliptin
The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.
- Trial name
- LAF33 (NCT01512797)
- Testing
- Sitagliptin phosphate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Blandine Laferrere
Hyperglycemia
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
The purpose of this study is to determine whether treatment with sitagliptin reduces the frequency and severity of high blood sugar (hyperglycemia) after cardiac surgery and to determine whether treatment with sitagliptin is…
- Trial name
- SITA-CABGDM (NCT02556918)
- Testing
- Sitagliptin, Regular Human Insulin, Insulin glargine
- Where
- 3 sites in United States
- Volunteers
- 202 people
- Sponsor
- Emory University
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin
This trial will be conducted in Africa, Asia, North America and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec) with sitagliptin, as add-on to subject's own current oral antidiabetic (OAD)…
- Trial name
- BEGIN™ (NCT01046110)
- Testing
- insulin degludec, sitagliptin
- Where
- 93 sites in United States, Argentina and 5 more
- Volunteers
- 458 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics
This study is intended to evaluate the pharmacodynamics, safety, and tolerability of LX4211 when administered concurrently with sitagliptin (Januvia®) in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01441232
- Testing
- LX4211, Januvia®
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Lexicon Pharmaceuticals
Reactive Hypoglycemia
Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism
The purpose of this study is to determine whether sitagliptin is effective in the treatment of reactive hypoglycemia by dysinsulinism.
- Trial name
- NCT00847080
- Testing
- Sitagliptin phosphate
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Cushing's Disease, Acromegaly
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
The study was designed to investigate the optimal management of hyperglycemia developed during pasireotide treatment in participants with Cushing's disease or Acromegaly, which was not manageable with metformin.
- Trial name
- NCT02060383
- Testing
- Pasireotide s.c., Sitagliptin, Liraglutide
- Where
- 43 sites in United States, Belgium and 10 more
- Volunteers
- 249 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Bone Loss, Postmenopausal
DPP4-Inhibitors and Bone Metabolism in Diabetes
Background Bone frailty and fractures are common conditions in patients with type 2 diabetes (T2D) and represent a major cause of morbidity and hospitalization in this population.
- Conditions
- Osteoporosis, Bone Loss, Postmenopausal, Diabetes Mellitus Type 2
- Trial name
- SlowDOWN (NCT06770894)
- Testing
- Sitagliptin 100 mg
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- Azienda Policlinico Umberto I
Type 1 Diabetes, Monogenic Diabetes
Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study
The purpose of this study is to evaluate the efficacy of adding oral hypoglycemic agents (OHA) to existing insulin treatment in monogenic variant carriers of the Joslin 50-Year Medalist Study ("Medalists"), who are characterized…
- Trial name
- NCT04409795
- Testing
- Metformin Extended Release Oral Tablet, Sitagliptin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Joslin Diabetes Center
Diabetes, Atherosclerosis
Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy
The study is being performed to determine whether sitagliptin, a dipeptidyl peptidase-4 inhibitor, both acutely and chronically improves blood vessel function.
- Trial name
- NCT01859793
- Testing
- sitagliptin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Medical College of Wisconsin